Menu Search
Equities

CareRx Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
29C1:FRA

CareRx Corp

Actions
  • Price (EUR)2.34
  • Today's Change0.02 / 0.86%
  • Shares traded20.00
  • 1 Year change+28.57%
  • Beta0.7465
Data delayed at least 15 minutes, as of Feb 16 2026 07:19 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CareRx Corporation is a Canada-based provider of pharmacy services to senior living communities. The Company serves approximately 88,000 residents in approximately 1,450 senior and other congregate care communities, including long-term care homes, retirement homes, assisted living facilities, and group homes. It has a network of pharmacy fulfillment centers located across the country. It supports its home care partners by providing solutions for the supply of chronic medication. It uses technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the safety and adherence for individuals with complex medication regimens. Revicare by CareRx is a distributor of medical supplies and continence care management products to residents in retirement and supportive living communities. The Company works with its home operator partners to promote resident health, staff education, and medication system quality and efficiency.

  • Revenue in CAD (TTM)366.34m
  • Net income in CAD93.00k
  • Incorporated2017
  • Employees1.42k
  • Location
    CareRx Corp320 Bay St. Suite 1200TORONTO M5H 4A6CanadaCAN
  • Phone+1 (647) 361-4499
  • Fax+1 (416) 927-8405
  • Websitehttps://www.carerx.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.